{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:41:26Z","timestamp":1769604086008,"version":"3.49.0"},"reference-count":104,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:00:00Z","timestamp":1648684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Center for Research and Development and the National Science Center","award":["TANGO-IV-C\/0012\/2019"],"award-info":[{"award-number":["TANGO-IV-C\/0012\/2019"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>Multiple illness is an increasingly common phenomenon. Its consequence is the need for polytherapy, which is particularly common among people suffering from arterial hypertension. The development of combined preparations (containing at least two API-active pharmaceutical ingredients) dedicated to the treatment of hypertension is a response to increased compliance, especially in elderly patients. In our work, we describe in particular the possibilities of using \u03b2-adrenergic receptors blockers and angiotensin-converting enzyme inhibitors in combinations. The combinations of APIs are used as single pills in patients with arterial hypertension with concomitant diseases such as hyperlipidemia; blood coagulation problems and diabetes mellitus were also discussed successively. Pharmacoeconomic analysis for the API combinations shown is also presented. As a final conclusion, numerous benefits of using the combined preparations should be indicated, especially by the elderly and\/or in patients with coexistence of other diseases.<\/jats:p>","DOI":"10.3390\/ijerph19074156","type":"journal-article","created":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T21:33:03Z","timestamp":1648762383000},"page":"4156","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Single-Pill Combination to Improve Hypertension Treatment: Pharmaceutical Industry Development"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0418-9336","authenticated-orcid":false,"given":"Magdalena","family":"Paczkowska-Walendowska","sequence":"first","affiliation":[{"name":"Department of Pharmacognosy, Poznan University of Medical Sciences, Rokietnicka 3, 60-806 Poznan, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6618-9956","authenticated-orcid":false,"given":"Szymon","family":"Sip","sequence":"additional","affiliation":[{"name":"Department of Pharmacognosy, Poznan University of Medical Sciences, Rokietnicka 3, 60-806 Poznan, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9062-0737","authenticated-orcid":false,"given":"Rafa\u0142","family":"Staszewski","sequence":"additional","affiliation":[{"name":"Department of Hypertension, Angiology and Internal Medicine, Poznan University of Medical Sciences, D\u0142uga 1\/2, 61-848 Pozna\u0144, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0891-5419","authenticated-orcid":false,"given":"Judyta","family":"Cielecka-Piontek","sequence":"additional","affiliation":[{"name":"Department of Pharmacognosy, Poznan University of Medical Sciences, Rokietnicka 3, 60-806 Poznan, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH)","volume":"39","author":"Williams","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_2","unstructured":"(2021, June 24). Hypertension. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hypertension."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0140-6736(05)17741-1","article-title":"Global Burden of Hypertension: Analysis of Worldwide Data","volume":"365","author":"Kearney","year":"2005","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1016\/j.amepre.2017.08.005","article-title":"Conducting Research on the Economics of Hypertension to Improve Cardiovascular Health","volume":"53","author":"Wang","year":"2017","journal-title":"Am. J. Prev. Med."},{"key":"ref_5","first-page":"i","article-title":"Polypharmacy: A Global Risk Factor for Elderly People","volume":"6","author":"Dagli","year":"2014","journal-title":"J. Int. Oral Health"},{"key":"ref_6","unstructured":"(2021, June 24). Medication Safety in Polypharmacy: Technical Report. Available online: https:\/\/www.who.int\/publications-detail-redirect\/medication-safety-in-polypharmacy-technical-report."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1520-037X.2007.06423.x","article-title":"Combination Polypharmacy for Cardiovascular Disease Prevention in Men: A Decision Analysis and Cost-Effectiveness Model","volume":"11","author":"Newman","year":"2008","journal-title":"Prev. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"34","DOI":"10.5603\/DK.2017.0006","article-title":"Pros and Cons of Polypharmacy in Elderly Patients with Diabetes","volume":"6","author":"Wojtczak","year":"2017","journal-title":"Clin. Diabetol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Janczura, M., Kobus-Moryson, M., Sip, S., \u017barowski, M., Ware\u0144czak, A., and Cielecka-Piontek, J. (2021). Fixed-Dose Combination of NSAIDs and Spasmolytic Agents in the Treatment of Different Types of Pain\u2014A Practical Review. J. Clin. Med., 10.","DOI":"10.3390\/jcm10143118"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/pme.12586","article-title":"Polypharmacy and Chronic Pain: Harm Exposure Is Not All about the Opioids","volume":"16","author":"Giummarra","year":"2015","journal-title":"Pain Med."},{"key":"ref_11","unstructured":"(2022, March 24). 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines|Hypertension. Available online: https:\/\/www.ahajournals.org\/doi\/10.1161\/HYP.0000000000000065."},{"key":"ref_12","unstructured":"(2022, March 24). 2020 International Society of Hypertension Global Hypertension Practice Guidelines|Hypertension. Available online: https:\/\/www.ahajournals.org\/doi\/10.1161\/HYPERTENSIONAHA.120.15026."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.recesp.2019.02.023","article-title":"Beta-Blockers: Historical Perspective and Mechanisms of Action","volume":"72","author":"Oliver","year":"2019","journal-title":"Rev. Esp. Cardiol. (Engl. Ed.)"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2174\/1389557515666151016125948","article-title":"Beta-Blockers: Current State of Knowledge and Perspectives","volume":"16","author":"Ogrodowczyk","year":"2016","journal-title":"Mini Rev. Med. Chem"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/5584_2016_36","article-title":"The Role of Beta-Blockers in the Treatment of Hypertension","volume":"956","author":"Cruickshank","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1755-5922.2011.00306.x","article-title":"Cardio-Selective Beta-Blocker: Pharmacological Evidence and Their Influence on Exercise Capacity","volume":"31","author":"Ladage","year":"2013","journal-title":"Cardiovasc. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/archinte.164.13.1389","article-title":"Adverse Effects of Beta-Blocker Therapy for Patients with Heart Failure: A Quantitative Overview of Randomized Trials","volume":"164","author":"Ko","year":"2004","journal-title":"Arch. Intern. Med."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Jackson, J.L., Kuriyama, A., Kuwatsuka, Y., Nickoloff, S., Storch, D., Jackson, W., Zhang, Z.-J., and Hayashino, Y. (2019). Beta-Blockers for the Prevention of Headache in Adults, a Systematic Review and Meta-Analysis. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0212785"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.4103\/0972-2327.83097","article-title":"Guidelines for Management of Essential Tremor","volume":"14","author":"Pal","year":"2011","journal-title":"Ann. Indian Acad. Neurol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S329","DOI":"10.4103\/2230-8210.86976","article-title":"Medical Management of Pheochromocytoma: Role of the Endocrinologist","volume":"15","author":"Garg","year":"2011","journal-title":"Indian J. Endocrinol. Metab."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1089\/jop.1993.9.373","article-title":"Topical Ophthalmic Beta Blockers: A Comparative Review","volume":"9","author":"Zimmerman","year":"1993","journal-title":"J. Ocul Pharm."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/ajhp\/57.suppl_1.S3","article-title":"Overview of the Angiotensin-Converting-Enzyme Inhibitors","volume":"57","author":"Piepho","year":"2000","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/gb-2003-4-8-225","article-title":"Angiotensin-I-Converting Enzyme and Its Relatives","volume":"4","author":"Riordan","year":"2003","journal-title":"Genome Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.2174\/1381612820666141112160013","article-title":"Chemistry and Pharmacology of Angiotensin-Converting Enzyme Inhibitors","volume":"21","author":"Regulski","year":"2015","journal-title":"Curr. Pharm. Des."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2165\/00002018-199207010-00004","article-title":"Adverse Effects of Angiotensin Converting Enzyme (ACE) Inhibitors. An Update","volume":"7","author":"Parish","year":"1992","journal-title":"Drug Saf."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1097\/HJH.0000000000001390","article-title":"The Polypill in Cardiovascular Prevention: Evidence, Limitations and Perspective\u2014Position Paper of the European Society of Hypertension","volume":"35","author":"Coca","year":"2017","journal-title":"J. Hypertens."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Baumgartner, A., Drame, K., Geutjens, S., and Airaksinen, M. (2020). Does the Polypill Improve Patient Adherence Compared to Its Individual Formulations? A Systematic Review. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12020190"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Rao, S., Jamal Siddiqi, T., Khan, M.S., Michos, E.D., Navar, A.M., Wang, T.J., Greene, S.J., Prabhakaran, D., Khera, A., and Pandey, A. (2022). Association of Polypill Therapy with Cardiovascular Outcomes, Mortality, and Adherence: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Prog. Cardiovasc. Dis., S0033-0620(22)00005-6.","DOI":"10.1016\/j.pcad.2022.01.005"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJMoa2028220","article-title":"Polypill with or without Aspirin in Persons without Cardiovascular Disease","volume":"384","author":"Yusuf","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2217\/cer-2021-0105","article-title":"Evaluating Patients\u2019 Satisfaction and Preferences with a Secondary Prevention Cardiovascular Polypill: The Aurora Study","volume":"10","author":"Hermans","year":"2021","journal-title":"J. Comp. Eff. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11886-015-0673-x","article-title":"Polypill: Progress and Challenges to Global Use--Update on the Trials and Policy Implementation","volume":"17","author":"Webster","year":"2015","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.5603\/KP.2017.0237","article-title":"Single-Pill Combinations (SPCs) and Treatment of Arterial Hypertension in Poland. Expert Consensus Statement of the Polish Society of Hypertension and Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy","volume":"75","author":"Tykarski","year":"2017","journal-title":"Kardiol. Pol."},{"key":"ref_33","first-page":"1","article-title":"Zasady post\u0119powania w nadci\u015bnieniu t\u0119tniczym\u20142019 rok","volume":"5","author":"Tykarski","year":"2019","journal-title":"Nadci\u015bnienie T\u0119tnicze W Prakt."},{"key":"ref_34","unstructured":"Center for Drug Evaluation and Research (2021, June 24). Nonclinical Safety Evaluation of Drug or Biologic Combinations, Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/nonclinical-safety-evaluation-drug-or-biologic-combinations."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Raj, G.M., and Raveendran, R. (2019). Fixed-Dose Combinations. Introduction to Basics of Pharmacology and Toxicology: Volume 1: General and Molecular Pharmacology: Principles of Drug Action, Springer.","DOI":"10.1007\/978-981-32-9779-1"},{"key":"ref_36","first-page":"967073","article-title":"The Effect on Treatment Adherence of Administering Drugs as Fixed-Dose Combinations versus as Separate Pills: Systematic Review and Meta-Analysis","volume":"2014","author":"Nellen","year":"2014","journal-title":"AIDS Res. Treat."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1097\/HJH.0000000000002381","article-title":"Impact of Single-Pill Combination Therapy on Adherence, Blood Pressure Control, and Clinical Outcomes: A Rapid Evidence Assessment of Recent Literature","volume":"38","author":"Tsioufis","year":"2020","journal-title":"J. Hypertens."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jama.2018.11439","article-title":"Medicare Spending on Brand-Name Combination Medications vs. Their Generic Constituents","volume":"320","author":"Sacks","year":"2018","journal-title":"JAMA"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jcjd.2018.01.011","article-title":"Single-Pill Combinations in the Treatment of Hypertension in Adults: Beyond Convenience","volume":"42","author":"Imbeault","year":"2018","journal-title":"Can. J. Diabetes"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Hao, J., Rodriguez-Monguio, R., and Seoane-Vazquez, E. (2015). Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0140708"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.amjmed.2008.09.038","article-title":"Combination Therapy versus Monotherapy in Reducing Blood Pressure: Meta-Analysis on 11,000 Participants from 42 Trials","volume":"122","author":"Wald","year":"2009","journal-title":"Am. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00392-007-0487-y","article-title":"Treatment of Heart Failure with ACE Inhibitors and Beta-Blockers","volume":"96","author":"Voors","year":"2007","journal-title":"Clin. Res. Cardiol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Task Force Members, Montalescot, G., Sechtem, U., Achenbach, S., Andreotti, F., Arden, C., Budaj, A., Bugiardini, R., Crea, F., and Cuisset, T. (2013). 2013 ESC Guidelines on the Management of Stable Coronary Artery Disease: The Task Force on the Management of Stable Coronary Artery Disease of the European Society of Cardiology. Eur. Heart J., 34, 2949\u20133003.","DOI":"10.1093\/eurheartj\/eht296"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Strauss, M.H., Hall, A.S., and Narkiewicz, K. (2021). The Combination of Beta-Blockers and ACE Inhibitors Across the Spectrum of Cardiovascular Diseases. Cardiovasc. Drugs.","DOI":"10.1007\/s10557-021-07248-1"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.ahj.2015.08.018","article-title":"Perindopril and \u03b2-Blocker for the Prevention of Cardiac Events and Mortality in Stable Coronary Artery Disease Patients: A EUropean Trial on Reduction Of Cardiac Events with Perindopril in Stable Coronary Artery Disease (EUROPA) Subanalysis","volume":"170","author":"Bertrand","year":"2015","journal-title":"Am. Heart J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"249","DOI":"10.20452\/pamw.2782","article-title":"Factors Associated with Resistant Hypertension in a Large Cohort of Hypertensive Patients: The Pol-Fokus Study","volume":"125","author":"Prejbisz","year":"2015","journal-title":"Pol. Arch. Med. Wewn."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3317\/jraas.2003.021","article-title":"Interaction of Beta-Blockers and Angiotensin Receptor Blockers\/ACE Inhibitors in Heart Failure","volume":"4","author":"Cohn","year":"2003","journal-title":"J. Renin Angiotensin Aldosterone Syst."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s11906-013-0340-9","article-title":"High Blood Pressure: The Leading Global Burden of Disease Risk Factor and the Need for Worldwide Prevention Programs","volume":"15","author":"Bromfield","year":"2013","journal-title":"Curr. Hypertens. Rep."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"672","DOI":"10.4070\/kcj.2016.46.5.672","article-title":"Prevalence of Comorbidity among People with Hypertension: The Korea National Health and Nutrition Examination Survey 2007\u20132013","volume":"46","author":"Noh","year":"2016","journal-title":"Korean Circ. J."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e535","DOI":"10.1161\/CIR.0000000000000450","article-title":"Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association","volume":"134","author":"Bozkurt","year":"2016","journal-title":"Circulation"},{"key":"ref_51","first-page":"805","article-title":"Adherence to Lipid-Lowering Treatment: The Patient Perspective","volume":"6","author":"Casula","year":"2012","journal-title":"Patient Prefer. Adherence"},{"key":"ref_52","first-page":"35","article-title":"Factors Affecting Adherence to Statins in Hypercholesterolemic Kuwaiti Patients: A Cross-Sectional Study","volume":"26","author":"Somerset","year":"2017","journal-title":"MPP"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s11606-008-0544-x","article-title":"Impact of Fixed-Dose Combination Drugs on Adherence to Prescription Medications","volume":"23","author":"Pan","year":"2008","journal-title":"J. Gen. Intern. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1470320319868890","DOI":"10.1177\/1470320319868890","article-title":"Effects of Combined Statin and ACE Inhibitor Therapy on Endothelial Function and Blood Pressure in Essential Hypertension\u2014a Randomised Double-Blind, Placebo Controlled Crossover Study","volume":"20","author":"Ruszkowski","year":"2019","journal-title":"J. Renin Angiotensin Aldosterone Syst."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ejvs.2004.07.008","article-title":"A Combination of Statins and Beta-Blockers Is Independently Associated with a Reduction in the Incidence of Perioperative Mortality and Nonfatal Myocardial Infarction in Patients Undergoing Abdominal Aortic Aneurysm Surgery","volume":"28","author":"Kertai","year":"2004","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/sj.jhh.1001748","article-title":"Effect of Statins and ACE Inhibitors Alone and in Combination on Clinical Outcome in Patients with Coronary Heart Disease","volume":"18","author":"Athyros","year":"2004","journal-title":"J. Hum. Hypertens"},{"key":"ref_57","unstructured":"Feingold, K.R., Anawalt, B., Boyce, A., Chrousos, G., de Herder, W.W., Dhatariya, K., Dungan, K., Grossman, A., Hershman, J.M., and Hofland, J. (2000). Guidelines for the Management of High Blood Cholesterol. Endotext, MDText.com, Inc."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/2042098612439884","article-title":"Safety of Statins: An Update","volume":"3","author":"Hu","year":"2012","journal-title":"Adv. Drug Saf."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e05417","DOI":"10.1016\/j.heliyon.2020.e05417","article-title":"Prevalence of Hyperlipidemia and Its Associated Factors in University Students in Colombia","volume":"6","year":"2020","journal-title":"Heliyon"},{"key":"ref_60","first-page":"S139","article-title":"Epidemiology and Management of Hyperlipidemia","volume":"23","author":"Karr","year":"2017","journal-title":"Am. J. Manag. Care"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.repc.2017.05.008","article-title":"Aspirin and Blood Pressure: Effects When Used Alone or in Combination with Antihypertensive Drugs","volume":"36","author":"Costa","year":"2017","journal-title":"Rev. Port. De Cardiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1097\/00004872-200205000-00038","article-title":"Low-Dose Aspirin Does Not Interfere with the Blood Pressure-Lowering Effects of Antihypertensive Therapy","volume":"20","author":"Zanchetti","year":"2002","journal-title":"J. Hypertens."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-2796.2001.00800.x","article-title":"Should Patients with Hypertension Receive Antithrombotic Therapy?","volume":"249","author":"Lip","year":"2001","journal-title":"J. Intern. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ahj.2016.05.001","article-title":"Blood Pressure Control and Stroke or Bleeding Risk in Anticoagulated Patients with Atrial Fibrillation: Results from the ROCKET AF Trial","volume":"178","author":"Vemulapalli","year":"2016","journal-title":"Am. Heart J."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Lip, G.Y.H., and Felmeden, D.C. (2004). Antiplatelet Agents and Anticoagulants for Hypertension. Cochrane Database Syst. Rev., CD003186.","DOI":"10.1002\/14651858.CD003186.pub2"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e002015","DOI":"10.1161\/JAHA.115.002015","article-title":"Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial","volume":"4","author":"Rao","year":"2015","journal-title":"J. Am. Heart Assoc."},{"key":"ref_67","first-page":"897","article-title":"Antiplatelet Therapy and Anticoagulation in Patients with Hypertension","volume":"71","author":"Griffin","year":"2005","journal-title":"AFP"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Abdelbagi, O., Musa, I.R., Musa, S.M., ALtigani, S.A., and Adam, I. (2021). Prevalence and Associated Factors of Hypertension among Adults with Diabetes Mellitus in Northern Sudan: A Cross-Sectional Study. BMC Cardiovasc. Disord., 21.","DOI":"10.1186\/s12872-021-01983-x"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/ajh\/hpy025","article-title":"Diabetes and Hypertension: Clinical Update","volume":"31","author":"Khangura","year":"2018","journal-title":"Am. J. Hypertens."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ecl.2013.09.005","article-title":"Type 2 Diabetes Mellitus and Hypertension: An Update","volume":"43","author":"Lastra","year":"2014","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"ref_71","first-page":"698","article-title":"Epidemiology of Diabetes","volume":"42","author":"Forouhi","year":"2014","journal-title":"Medicine (Abingdon)"},{"key":"ref_72","first-page":"281","article-title":"The Current Total Economic Burden of Diabetes Mellitus in the Netherlands","volume":"75","author":"Peters","year":"2017","journal-title":"Neth. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1161\/CIRCRESAHA.118.314487","article-title":"Type 2 Diabetes and Hypertension","volume":"124","author":"Sun","year":"2019","journal-title":"Circ. Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1186\/2193-1801-3-644","article-title":"Epidemiology of Hypertension and Its Relationship with Type 2 Diabetes and Obesity in Eastern Morocco","volume":"3","author":"Ziyyat","year":"2014","journal-title":"Springerplus"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.clinthera.2007.07.010","article-title":"Comorbidity of Diabetes Mellitus and Hypertension in the Clinical Setting: A Review of Prevalence, Pathophysiology, and Treatment Perspectives","volume":"29","author":"Bretzel","year":"2007","journal-title":"Clin. Ther."},{"key":"ref_76","first-page":"1277","article-title":"Pharmacologic Management of Hypertension in Patients with Diabetes","volume":"78","author":"Whalen","year":"2008","journal-title":"AFP"},{"key":"ref_77","first-page":"981","article-title":"A Practical Approach to Hypertension Management in Diabetes","volume":"8","author":"Shaikh","year":"2017","journal-title":"Diabetes"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12933-016-0485-3","article-title":"Blood Pressure Control in Type 2 Diabetic Patients","volume":"16","author":"Grossman","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s12325-014-0107-y","article-title":"Efficacy and Tolerability of Fixed-Dose Combination of Perindopril\/Indapamide in Type 2 Diabetes Mellitus: PICASSO Trial","volume":"31","author":"Farsang","year":"2014","journal-title":"Adv. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/jch.13240","article-title":"Fixed-Dose vs Free-Dose Combinations for the Management of Hypertension-An Analysis of 81,958 Patients","volume":"20","author":"Bramlage","year":"2018","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.4158\/EP14259.RA","article-title":"Fixed-Dose Combination Therapy in Type 2 Diabetes Mellitus 1","volume":"20","author":"Blonde","year":"2014","journal-title":"Endocr. Pract."},{"key":"ref_82","unstructured":"(2021, June 24). FDC New Drugs Marketing, Available online: https:\/\/cdsco.gov.in\/opencms\/opencms\/en\/Approval_new\/FDC-New-Drugs-Marketing\/."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.5114\/aoms.2020.92689","article-title":"A Global Perspective on the Costs of Hypertension: A Systematic Review","volume":"16","author":"Wierzejska","year":"2020","journal-title":"Arch. Med. Sci."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/jch.13426","article-title":"Fixed-Dose Combination Pharmacologic Therapy to Improve Hypertension Control Worldwide: Clinical Perspective and Policy Implications","volume":"21","author":"DiPette","year":"2019","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s40292-020-00370-5","article-title":"Single Pill Regimen Leads to Better Adherence and Clinical Outcome in Daily Practice in Patients Suffering from Hypertension and\/or Dyslipidemia: Results of a Meta-Analysis","volume":"27","author":"Weisser","year":"2020","journal-title":"High Blood Press Cardiovasc. Prev."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s11606-016-3972-z","article-title":"Effect of Combination Therapy on Adherence Among US Patients Initiating Therapy for Hypertension: A Cohort Study","volume":"32","author":"Lauffenburger","year":"2017","journal-title":"J. Gen. Intern. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1161\/HYPERTENSIONAHA.120.15781","article-title":"Adherence to Single-Pill Versus Free-Equivalent Combination Therapy in Hypertension: A Systematic Review and Meta-Analysis","volume":"77","author":"Parati","year":"2021","journal-title":"Hypertension"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/j.1751-7176.2011.00550.x","article-title":"Single-Pill vs Free-Equivalent Combination Therapies for Hypertension: A Meta-Analysis of Health Care Costs and Adherence","volume":"13","author":"Sherrill","year":"2011","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1185\/03007995.2010.494462","article-title":"Evaluation of Compliance and Health Care Utilization in Patients Treated with Single Pill vs. Free Combination Antihypertensives","volume":"26","author":"Yang","year":"2010","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Verma, A.A., Khuu, W., Tadrous, M., Gomes, T., and Mamdani, M.M. (2018). Fixed-Dose Combination Antihypertensive Medications, Adherence, and Clinical Outcomes: A Population-Based Retrospective Cohort Study. PLoS Med., 15.","DOI":"10.1371\/journal.pmed.1002584"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"576","DOI":"10.3111\/13696998.2011.596873","article-title":"Comparison of Real-World Adherence, Healthcare Resource Utilization and Costs for Newly Initiated Valsartan\/Amlodipine Single-Pill Combination versus Angiotensin Receptor Blocker\/Calcium Channel Blocker Free-Combination Therapy","volume":"14","author":"Baser","year":"2011","journal-title":"J. Med. Econ."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1185\/03007995.2015.1098598","article-title":"Comparison of Amlodipine\/Valsartan\/Hydrochlorothiazide Single Pill Combination and Free Combination: Adherence, Persistence, Healthcare Utilization and Costs","volume":"31","author":"Machnicki","year":"2015","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/jch.12449","article-title":"Clinical Outcomes and Healthcare Costs in Hypertensive Patients Treated with a Fixed-Dose Combination of Amlodipine\/Valsartan","volume":"17","author":"Tung","year":"2015","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"768","DOI":"10.5603\/KP.a2015.0089","article-title":"Economic Evaluation of Single-Pill Combination of Indapamide and Amlodipine in the Treatment of Arterial Hypertension in the Polish Setting","volume":"73","author":"Kawalec","year":"2015","journal-title":"Kardiol. Pol. (Pol. Heart J.)"},{"key":"ref_95","first-page":"829","article-title":"Cost-Effectiveness Analysis of Antihypertensive Triple Combination Therapy among Patients Enrolled in a Medicare Advantage Plan","volume":"21","author":"Wang","year":"2021","journal-title":"Expert Rev. Pharm. Outcomes Res."},{"key":"ref_96","first-page":"209","article-title":"Drug Adherence to Olmesartan\/Amlodipine Fixed Combination in an Italian Clinical Practice Setting","volume":"6","author":"Saragoni","year":"2014","journal-title":"Clin. Outcomes Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s40292-019-00336-2","article-title":"Treatment with Free Triple Combination Therapy of Atorvastatin, Perindopril, Amlodipine in Hypertensive Patients: A Real-World Population Study in Italy","volume":"26","author":"Perrone","year":"2019","journal-title":"High Blood Press Cardiovasc. Prev."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40885-021-00177-z","article-title":"Real-World Evidence on the Strategy of Olmesartan-Based Triple Single-Pill Combination in Korean Hypertensive Patients: A Prospective, Multicenter, Observational Study (RESOLVE-PRO)","volume":"27","author":"Sohn","year":"2021","journal-title":"Clin. Hypertens."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1080\/13696998.2019.1699799","article-title":"Economic Evaluation of Olmesartan\/Amlodipine Fixed-Dose Combination for Hypertension Treatment in China","volume":"23","author":"Ren","year":"2020","journal-title":"J. Med. Econ."},{"key":"ref_100","first-page":"678","article-title":"Medication Adherence to Antihypertensive Triple-Combination Therapy Among Patients Enrolled in a Medicare Advantage Plan","volume":"25","author":"Wang","year":"2019","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"AMP019","DOI":"10.1161\/circ.125.suppl_10.AMP019","article-title":"Abstract MP019: Should Global Cardiovascular Risk Guide Treatment of Stage One Hypertension? A Cost-Effectiveness Analysis","volume":"125","author":"Moran","year":"2012","journal-title":"Circulation"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13063-018-2559-x","article-title":"Management of Hypertension and Multiple Risk Factors to Enhance Cardiovascular Health in Singapore: The SingHypertension Cluster Randomized Trial","volume":"19","author":"Jafar","year":"2018","journal-title":"Trials"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1185\/03007995.2012.729505","article-title":"Are Fixed-Dose Combination Antihypertensives Suitable as First-Line Therapy?","volume":"28","author":"Kjeldsen","year":"2012","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(19)31629-0","article-title":"Fixed-Dose Combination Antihypertensive Medications","volume":"394","author":"Benjamin","year":"2019","journal-title":"Lancet"}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/7\/4156\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:47:34Z","timestamp":1760136454000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/7\/4156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,31]]},"references-count":104,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["ijerph19074156"],"URL":"https:\/\/doi.org\/10.3390\/ijerph19074156","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,31]]}}}